| 34.5283 -0.002 (-0%) | 04-20 09:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.6 | 1-year : | 49.76 |
| Resists | First : | 36.47 | Second : | 42.6 |
| Pivot price | 33.6 |
|||
| Supports | First : | 30.62 | Second : | 27 |
| MAs | MA(5) : | 33.82 |
MA(20) : | 32.38 |
| MA(100) : | 30.75 |
MA(250) : | 29.96 |
|
| MACD | MACD : | 1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 65 |
D(3) : | 65.3  |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 36.47 | Low : | 25.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALKS ] has closed below upper band by 36.1%. Bollinger Bands are 35% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.76 - 34.89 | 34.89 - 35 |
| Low: | 33.76 - 33.92 | 33.92 - 34.05 |
| Close: | 34.28 - 34.54 | 34.54 - 34.74 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Sun, 19 Apr 2026
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
Sun, 19 Apr 2026
(ALKS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Thu, 16 Apr 2026
Alkermes (ALKS) Unveils Promising Data on Alixorexton for Narcol - GuruFocus
Thu, 16 Apr 2026
Narcolepsy patients showed 13 weeks of gains in Alkermes study - Stock Titan
Thu, 16 Apr 2026
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Mon, 13 Apr 2026
Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 166 (M) |
| Shares Float | 154 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 111.1 (%) |
| Shares Short | 19,010 (K) |
| Shares Short P.Month | 18,200 (K) |
| EPS | 1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.98 |
| Profit Margin | 16.3 % |
| Operating Margin | 15.1 % |
| Return on Assets (ttm) | 6.9 % |
| Return on Equity (ttm) | 14.7 % |
| Qtrly Rev. Growth | -10.7 % |
| Gross Profit (p.s.) | 7.69 |
| Sales Per Share | 8.9 |
| EBITDA (p.s.) | 1.69 |
| Qtrly Earnings Growth | -67 % |
| Operating Cash Flow | 521 (M) |
| Levered Free Cash Flow | -363 (M) |
| PE Ratio | 24.14 |
| PEG Ratio | 1.9 |
| Price to Book value | 3.14 |
| Price to Sales | 3.87 |
| Price to Cash Flow | 11.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|